We are live on ! Find out more
ANGO icon

AngioDynamics

130 hedge funds and large institutions have $492M invested in AngioDynamics in 2016 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 66 increasing their positions, 28 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

63,800% more call options, than puts

Call options by funds: $639K | Put options by funds: $1K

136% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 28

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

34% more capital invested

Capital invested by funds: $366M → $492M (+$125M)

8% more funds holding

Funds holding: 120130 (+10)

Holders
130
Holders Change
+10
Holders Change %
+8.33%
% of All Funds
3.47%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
18
Increased
66
Reduced
28
Closed
8
Calls
$639K
Puts
$1K
Net Calls
+$638K
Net Calls Change
+$347K

ANGO Hedge Fund Activity: Q3 2016 in Review

130 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in AngioDynamics (ANGO) for Q3 2016, worth a combined $492M — up 34% from $366M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ANGO positions and 8 closed out — a net gain of 10 holders — while 66 added to existing stakes and 28 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $18.2M. The largest seller was Broadfin Capital, cutting an estimated $11.6M.

  • 130 institutional investors held AngioDynamics (ANGO) as of Q3 2016, up from 120 in Q2 2016.
  • Funds reported $492M of AngioDynamics stock for Q3 2016, up 34% quarter-over-quarter.
  • 18 funds opened new AngioDynamics positions in Q3 2016 and 8 closed out, a net change of +10 holders.
  • The largest AngioDynamics buyer in Q3 2016 was Fidelity Investments, an estimated $18.2M added.
  • The largest AngioDynamics seller in Q3 2016 was Broadfin Capital, an estimated $11.6M sold.

Based on aggregated 13F filings for Q3 2016.